AnalystsMatthew BieglerMatthew Biegler's Stock Forecasts
AnalystsMatthew Biegler
Analyst Ranking
Bottom 6%
#4986 out of 5271 analysts
Average Return
-3.94%
Win Rate
36%36 out of 101
Risk vs Reward
Poor
Good
Matthew Biegler's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Olema Pharmaceuticals IncOLMA | +254.38% | $4.11 | $14.57 | 2025-03-18 - 2026-03-18 | Buy |
Olema Pharmaceuticals IncOLMA | +236.22% | $4.50 | $15.13 | 2025-05-13 - 2026-05-07 | Buy |
Fate Therapeutics IncFATE | +222.98% | $24.80 | $80.10 | 2020-04-05 - 2021-04-06 | Buy |
Oric Pharmaceuticals IncORIC | +202.61% | $4.99 | $15.10 | 2023-03-15 - 2024-03-15 | Buy |
Aptose Biosciences IncAPTOF | +189.86% | $931.51 | $2,700.04 | 2019-01-24 - 2020-01-24 | Buy |
Matthew Biegler Analyst Color
Get additional color on Matthew Biegler's coverage of popular stocks
Matthew Biegler's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Aprea Therapeutics IncAPRE | 1 | Buy | $5.00 | +467.54% | Initiates Coverage On | a day ago |
Relay Therapeutics IncRLAY | 7 | Buy | $18.00 | +43.88% | Maintains | 10 days ago |
Tyra Biosciences IncTYRA | 7 | Buy | $50.00 | +51.98% | Maintains | 3 months ago |
Regeneron Pharmaceuticals IncREGN | 1 | Buy | $865.00 | +21.99% | Reiterates | 3 months ago |
Olema Pharmaceuticals IncOLMA | 10 | Buy | $48.00 | +217.25% | Maintains | 5 months ago |
Ascentage Pharma Group InternationalAAPG | 1 | Buy | $45.00 | +107.37% | Initiates Coverage On | 5 months ago |
Oric Pharmaceuticals IncORIC | 6 | Buy | $15.00 | +70.26% | Maintains | 6 months ago |
Bridgebio Oncology Therapeutics IncBBOT | 2 | Buy | $22.00 | +179.90% | Maintains | 6 months ago |
Nurix Therapeutics IncNRIX | 3 | Buy | $28.00 | +71.99% | Maintains | 7 months ago |
Acrivon Therapeutics IncACRV | 4 | Buy | $8.00 | +294.09% | Maintains | 9 months ago |
Cytomx Therapeutics IncCTMX | 1 | Buy | $7.00 | +75.00% | Initiates Coverage On | 9 months ago |
Allogene Therapeutics IncALLO | 2 | Buy | $9.00 | +296.48% | Maintains | a year ago |
Vor Biopharma IncVOR | 7 | Buy | $160.00 | N/A | Reiterates | a year ago |
Arvinas IncARVN | 5 | Buy | $45.00 | N/A | Maintains | a year ago |
Gilead Sciences IncGILD | 1 | Buy | $115.00 | N/A | Reiterates | a year ago |
Ideaya Biosciences IncIDYA | 5 | Buy | $53.00 | N/A | Reiterates | 2 years ago |
Zentalis Pharmaceuticals IncZNTL | 7 | Buy | $20.00 | N/A | Reiterates | 2 years ago |
Blueprint Medicines CorpBPMC | 5 | Buy | $125.00 | N/A | Maintains | 2 years ago |
Cartesian Therapeutics IncRNAC | 3 | Buy | $50.00 | N/A | Reiterates | 2 years ago |
Fulcrum Therapeutics IncFULC | 5 | Buy | $14.00 | N/A | Maintains | 2 years ago |
Alpine Immune Sciences IncALPN | 1 | Buy | $44.00 | N/A | Reiterates | 2 years ago |
Medicenna Therapeutics CorpMDNAF | 3 | Buy | $3.00 | N/A | Maintains | 3 years ago |
Aptose Biosciences IncAPTOF | 5 | Buy | $450.00 | N/A | Maintains | 3 years ago |
Ambrx Biopharma IncAMAM | 1 | Buy | $30.00 | N/A | Initiates Coverage On | 3 years ago |
Alphaton Capital CorpALP | 1 | Buy | $360.00 | N/A | Maintains | 3 years ago |
Nkarta IncNKTX | 2 | Buy | $36.00 | N/A | Maintains | 3 years ago |
Celularity IncCELU | 1 | Buy | $90.00 | N/A | Initiates Coverage On | 4 years ago |
Turning Point Therapeutics IncTPTX | 3 | Buy | $105.00 | N/A | Maintains | 4 years ago |
Fate Therapeutics IncFATE | 1 | Buy | $34.00 | N/A | Maintains | 6 years ago |
Q32 Bio IncQTTB | 1 | Buy | $576.00 | N/A | Upgrades | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.